Charles Schwab Investment Management Inc. Has $3.36 Million Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Charles Schwab Investment Management Inc. boosted its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 35.5% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 253,551 shares of the company's stock after acquiring an additional 66,386 shares during the period. Charles Schwab Investment Management Inc.'s holdings in Takeda Pharmaceutical were worth $3,357,000 as of its most recent filing with the SEC.

A number of other large investors also recently made changes to their positions in the stock. Schechter Investment Advisors LLC boosted its stake in Takeda Pharmaceutical by 2.5% during the 4th quarter. Schechter Investment Advisors LLC now owns 119,668 shares of the company's stock worth $1,584,000 after acquiring an additional 2,884 shares during the last quarter. Sage Rhino Capital LLC increased its position in shares of Takeda Pharmaceutical by 14.9% in the 4th quarter. Sage Rhino Capital LLC now owns 11,840 shares of the company's stock valued at $157,000 after buying an additional 1,538 shares in the last quarter. Smartleaf Asset Management LLC raised its stake in Takeda Pharmaceutical by 389.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 10,020 shares of the company's stock worth $132,000 after buying an additional 7,972 shares during the period. US Bancorp DE raised its stake in Takeda Pharmaceutical by 21.2% during the 4th quarter. US Bancorp DE now owns 124,332 shares of the company's stock worth $1,646,000 after buying an additional 21,744 shares during the period. Finally, Fisher Asset Management LLC bought a new position in Takeda Pharmaceutical during the fourth quarter worth about $547,000. Institutional investors and hedge funds own 9.17% of the company's stock.

Remove Ads

Takeda Pharmaceutical Trading Down 1.8 %

NYSE:TAK traded down $0.28 on Monday, reaching $14.77. The company's stock had a trading volume of 267,396 shares, compared to its average volume of 1,793,658. The firm has a market cap of $47.01 billion, a PE ratio of 36.93, a PEG ratio of 0.24 and a beta of 0.46. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31. The business's 50-day moving average price is $14.16 and its two-hundred day moving average price is $13.92. Takeda Pharmaceutical Company Limited has a 1-year low of $12.58 and a 1-year high of $15.31.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its quarterly earnings data on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. Equities research analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.